Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat Extension Study in Myeloproliferative Neoplasms
NCT06351631Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Primary completion
- Dec 2034
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of bomedemstat in essential thrombocythemia (ET), myelofibrosis (MF), polycythemia vera (PV), sponsored by Merck & Co.. Started May 2024; status: recruiting.
02
Drugs
bomedemstat
03
Conditions
essential thrombocythemia (ET)myelofibrosis (MF)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06351631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351631.